Enliven Therapeutics, Inc. announced that it has entered into a securities purchase agreement to issue 5,357,144 shares at a price of $14 per share for the gross proceeds of $75,000,016 and pre funded warrants at a price of $13.999 per warrant for the total gross proceeds of $90,000,000 on March 19, 2024. The Pre-Funded Warrants will be exercisable into 1,071,505 shares and will have an exercise price of $0.001 per share of common stock.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.22 USD | -3.01% | +1.40% | +67.77% |
May. 20 | Enliven Therapeutics Insider Sold Shares Worth $22,877,262, According to a Recent SEC Filing | MT |
May. 14 | Enliven Therapeutics Q1 Loss Narrows | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.77% | 1.13B | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ELVN Stock
- News Enliven Therapeutics, Inc.
- Enliven Therapeutics, Inc. announced that it expects to receive $90.000014 million in funding